Mass Spectrometry: Advances for Drug Discovery
Innovative Advances in Pre and Early Clinical Drug Discovery
Mass spectrometry (MS) has been widely used in the drug discovery pipeline for many years. Recent developments in the field have increased both the impact and application of this technology platform, even enabling MS to reach through into a support role in surgical situations. Few technologies have the power to deliver the depth and quality of data from such a range of samples as mass spectrometry making this a true high content biology platform.
MS has become the cornerstone technology in the “omics” revolution. Increased sensitivity and mass resolution have led to enhanced capabilities in proteomics and are enabling rapid growth in metabolic and phenomic profiling of clinical patients. Increasingly, metabolomics and proteomics are being used in a pre-clinical setting to establish the mode of action of drugs in both the efficacy and toxicity setting. Advances in ionisation techniques are enabling wider use of MS as a tool for high content cell imaging.
In keeping with the ELRIG philosophy of bringing together scientific leaders from biopharma and academia to share cutting edge knowledge, this event will focus on recent innovative advances in the field of MS. Throughout the day, speakers will present both an over view of how mass spectrometry is impacting in clinical and pre-clinical settings and also how new applications and technology are driving forward the science and our understanding of disease.
Specific topics include the following.
• Advances in MS Imaging – from screening to cellular imaging
• Metabolomics – Clinical possibilities and technical challenges
• Proteomics – Current state-of-the-art advancements
• Synthetic Biology – Driving enzyme evolution
• Live Cell Applications – Direct analysis from cells
University of Manchester